Comparison between PD ‐1/PD‐L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model

International Journal of Cancer, EarlyView.

Source: International Journal of Cancer - September 25, 2018 Category: Cancer & Oncology Authors: Yingcheng Wu, Lifeng Lin, Yanting Shen, Huiqun Wu Source Type: research